Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Kaletra Tops 12% Of PI Market; Synthroid Outlook Is "Very Good"

Executive Summary

Abbott expects to claim the number one spot in the protease inhibitor market by the end of 2001 on the strength of the first-year performance of Kaletra (ritonavir/lopinavir).

You may also be interested in...



Abbott Synthroid NDA To Include Clinical Study Data; Citizen Petition Rejected

Abbott will file data from clinical studies, including bioavailability and pharmacokinetic data, to support its NDA for the thyroid agent Synthroid.

GSK/Vertex Agenerase Prodrug To Target Protease Inhibitor-Naive Patients

GlaxoSmithKline/Vertex' Agenerase prodrug will target first-time protease inhibitor patients, a market segment that amprenavir has not penetrated, Vertex VP-Corporate Communications Lynne Brum told analysts during a recent conference call.

Abbott Synthroid NDA To Include Clinical Study Data; Citizen Petition Rejected

Abbott will file data from clinical studies, including bioavailability and pharmacokinetic data, to support its NDA for the thyroid agent Synthroid.

UsernamePublicRestriction

Register

PS037643

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel